Here is the meat of the release.MELBOURNE, Australia and...

Here is the meat of the release.

MELBOURNE, Australia and PRINCETON, N.J., May 28, 2024 -- Opthea Limited
(ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical
company developing novel therapies to treat highly prevalent and progressive retinal
diseases, including wet age-related macular degeneration (wet AMD), today announced
that it has now completed enrollment in both the COAST and ShORe trials constituting
its pivotal Phase 3 clinical program. This program is designed to assess the safety and
superior efficacy of sozinibercept in combination with standard-of-care anti-VEGF-A
therapies compared to standard of care alone for the treatment of patients with wet AMD.
“Today marks the achievement of a key milestone for the sozinibercept global Phase 3
clinical trial program that brings us closer to our goal of improving visual outcomes for
patients with wet AMD,” said Arshad M. Khanani, MD, MA, FASRS, Chief Medical Advisor
of Opthea. “In a large Phase 2b clinical trial of 366 treatment-naïve wet AMD patients,
sozinibercept demonstrated strong clinical evidence of superior visual outcomes in
combination with ranibizumab. These data formed the basis for this large, global Phase
3 clinical program.”